Non-Small Cell Lung Cancer - Completely Resectable Clinical Trial
Official title:
L-Vax: A Feasibility Study Using a DNP-Modified Autologous Tumor Cell Vaccine as Therapy in Patients With Resectable Non-Small Cell Lung Cancer
To determine if a vaccine made from patient's own tumor tissue can stimulate an immune response against the patient's tumor cells. To determine the safety of the vaccine
Study Objectives: To study the toxicity, safety and delayed-type hypersensitivity (DTH)
responses of DNP-modified autologous tumor cell vaccine (L-Vax) in patients with resectable
NSCLC:
- To determine the tolerability and toxicity of L-Vax
- To determine whether L-Vax induces a DTH response to autologous, DNP-modified NSCLC
cells of similar magnitude to responses observed with melanoma
- Determine whether L-Vax induces a DTH response to autologous unmodified NSCLC cells
- To determine whether the DTH responses to autologous, unmodified NSCLC cells that have
been fixed with ethanol correlate with DTH responses to autologous, unmodified NSCLC
cells that are not fixed
Study Population: Patients with resectable NSCLC whose therapeutic tumor surgery provides a
mass, which yields adequate tumor, cells for vaccine preparation and DTH testing
Study Design: A Phase I/IIa double-blind, three-dose, single center study
Investigational Product: L-Vax: DNP-modified autologous NSCLC cell vaccine
Dosage Form: Cell suspension
Route of Administration: Intradermal
Dosage and Treatment Schedule: Prior to vaccine administration, patients will be tested for
DTH to autologous NSCLC cells that have been: DNP-modified, or unmodified and irradiated, or
unmodified and irradiated and fixed with ethanol (if sufficient cells available) Three doses
of vaccine will be tested: 5 x 105, 2.5 x 106, or 5 x 106 DNP-modified autologous NSCLC
cells. An initial dose of DNP-modified autologous NSCLC cells* without Bacillus of Calmette
and Guérin (BCG) followed by cyclophosphamide (CY) then weekly doses of DNP-modified
autologous NSCLC tumor cells mixed with BCG for 6 weeks, and completed with one dose of
DNP-modified autologous NSCLC tumor cells mixed with BCG as a 6-month booster, if adequate
number of cells available.
- count determined prior to aliquoting for cryopreservation
Endpoints: Treatment-emergent and related adverse events, serious adverse events, and Grade
3 and 4 laboratory abnormalities for safety assessments
Other Parameters: · DTH skin reactions for assessing the induction of immune responses to
DNP-modified and unmodified autologous NSCLC tumor cells· Survival· Exploratory analysis of
in vitro studies of peripheral blood lymphocytes obtained from study subjects
Duration of Treatment: Up to 9 months
Duration of Subject Participation in Study: Three months from the patient's last vaccine
Duration of Follow-up: Survival information and disease status will be collected via phone
or visit on a quarterly basis for each patient beginning 30 days after the last scheduled
visit until the last patient has been followed for three months from his/her last vaccine
Number of Subjects Required to Meet Protocol Objectives: Up to 42 evaluable subjects
Number of Study Centers: Three
Number of Individual Blood Draws: 15 draws over nine months
Volume of Blood Drawn: 13 Draws of 30 mL/draw (total 360 mL) and two draws of 50mL in
heparinized tubes
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment